FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262857054> ?p ?o ?g. }

• W2262857054 endingPage "299" @default.
• W2262857054 startingPage "294" @default.
• W2262857054 abstract "Pre-treatment lymphocytopaenia may result from cytokines secreted by the tumour microenvironment in association with aggressive tumour biology. We sought to establish the prognostic significance of lymphocytopaenia in muscle-invasive and advanced bladder cancer.Seventy-four patients with muscle-invasive bladder cancer treated with radical chemoradiotherapy and 131 patients with advanced bladder cancer treated with palliative chemotherapy were included in the study. The absolute lymphocyte count on the first day of treatment was recorded. Invasive local or systemic recurrence in the muscle-invasive bladder cancer cohort and all-cause mortality in the advanced bladder cancer cohort were defined as survival end points. Receiver operating characteristic (ROC) curve analysis was utilized to determine the cut-off for defining lymphocytopaenia in the muscle-invasive bladder cancer cohort followed by multivariable analysis in a model evaluating the following variables: anaemia, neutrophilia, tumour stage, hydronephrosis and neoadjuvant chemotherapy. Subsequently, lymphocytopaenia was assessed in a multivariable model of the advanced bladder cancer cohort analysing the following prognostic variables: neutrophilia, anaemia, performance status and presence of bone or visceral metastases. A further analysis was carried out evaluating absolute lymphocyte count as a continuous variable.An absolute lymphocyte count of 1.5 × 10(9)/l was determined as the cut-off on ROC curve analysis in the muscle-invasive bladder cancer cohort, and multivariate analysis revealed that only lymphocytopaenia was predictive for inferior outcome in this cohort. In the advanced bladder cancer cohort, lymphocytopaenia [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.1-2.4; P = 0.02] and performance status (HR 1.7, 95% CI 1.0-2.7; P = 0.047) were adverse prognostic factors in the binary variable multivariate model. Absolute lymphocyte count was the sole significant factor when analysed as a continuous variable (HR 0.66, 95% CI 0.5-0.87; P = 0.003).Pre-treatment lymphocytopaenia is an independent adverse prognostic factor in both muscle-invasive and advanced bladder cancer. It may be a manifestation of cancer-induced immune suppression driving tumour progression." @default.
• W2262857054 created "2016-06-24" @default.
• W2262857054 creator A5008438464 @default.
• W2262857054 creator A5019654104 @default.
• W2262857054 creator A5041859071 @default.
• W2262857054 creator A5053874003 @default.
• W2262857054 creator A5062185552 @default.
• W2262857054 creator A5073399228 @default.
• W2262857054 creator A5076098983 @default.
• W2262857054 creator A5079894409 @default.
• W2262857054 date "2016-02-01" @default.
• W2262857054 modified "2023-10-14" @default.
• W2262857054 title "Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer" @default.
• W2262857054 cites W1587849076 @default.
• W2262857054 cites W1595607998 @default.
• W2262857054 cites W1970602197 @default.
• W2262857054 cites W1971208896 @default.
• W2262857054 cites W1980391093 @default.
• W2262857054 cites W1985950314 @default.
• W2262857054 cites W1986925527 @default.
• W2262857054 cites W1999523969 @default.
• W2262857054 cites W2004505677 @default.
• W2262857054 cites W2044425811 @default.
• W2262857054 cites W2046212846 @default.
• W2262857054 cites W2049491375 @default.
• W2262857054 cites W2055461546 @default.
• W2262857054 cites W2073789795 @default.
• W2262857054 cites W2074484141 @default.
• W2262857054 cites W2088966130 @default.
• W2262857054 cites W2093424661 @default.
• W2262857054 cites W2101562875 @default.
• W2262857054 cites W2125675894 @default.
• W2262857054 cites W2130834017 @default.
• W2262857054 cites W2148237316 @default.
• W2262857054 cites W2164361265 @default.
• W2262857054 cites W2170705825 @default.
• W2262857054 cites W4243650202 @default.
• W2262857054 doi "https://doi.org/10.1093/annonc/mdv546" @default.
• W2262857054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26578732" @default.
• W2262857054 hasPublicationYear "2016" @default.
• W2262857054 type Work @default.
• W2262857054 sameAs 2262857054 @default.
• W2262857054 citedByCount "43" @default.
• W2262857054 countsByYear W22628570542016 @default.
• W2262857054 countsByYear W22628570542017 @default.
• W2262857054 countsByYear W22628570542018 @default.
• W2262857054 countsByYear W22628570542019 @default.
• W2262857054 countsByYear W22628570542020 @default.
• W2262857054 countsByYear W22628570542021 @default.
• W2262857054 countsByYear W22628570542022 @default.
• W2262857054 countsByYear W22628570542023 @default.
• W2262857054 crossrefType "journal-article" @default.
• W2262857054 hasAuthorship W2262857054A5008438464 @default.
• W2262857054 hasAuthorship W2262857054A5019654104 @default.
• W2262857054 hasAuthorship W2262857054A5041859071 @default.
• W2262857054 hasAuthorship W2262857054A5053874003 @default.
• W2262857054 hasAuthorship W2262857054A5062185552 @default.
• W2262857054 hasAuthorship W2262857054A5073399228 @default.
• W2262857054 hasAuthorship W2262857054A5076098983 @default.
• W2262857054 hasAuthorship W2262857054A5079894409 @default.
• W2262857054 hasBestOaLocation W22628570541 @default.
• W2262857054 hasConcept C121608353 @default.
• W2262857054 hasConcept C126322002 @default.
• W2262857054 hasConcept C126894567 @default.
• W2262857054 hasConcept C143998085 @default.
• W2262857054 hasConcept C207103383 @default.
• W2262857054 hasConcept C2777802486 @default.
• W2262857054 hasConcept C2780352672 @default.
• W2262857054 hasConcept C44249647 @default.
• W2262857054 hasConcept C71924100 @default.
• W2262857054 hasConcept C72563966 @default.
• W2262857054 hasConceptScore W2262857054C121608353 @default.
• W2262857054 hasConceptScore W2262857054C126322002 @default.
• W2262857054 hasConceptScore W2262857054C126894567 @default.
• W2262857054 hasConceptScore W2262857054C143998085 @default.
• W2262857054 hasConceptScore W2262857054C207103383 @default.
• W2262857054 hasConceptScore W2262857054C2777802486 @default.
• W2262857054 hasConceptScore W2262857054C2780352672 @default.
• W2262857054 hasConceptScore W2262857054C44249647 @default.
• W2262857054 hasConceptScore W2262857054C71924100 @default.
• W2262857054 hasConceptScore W2262857054C72563966 @default.
• W2262857054 hasIssue "2" @default.
• W2262857054 hasLocation W22628570541 @default.
• W2262857054 hasLocation W22628570542 @default.
• W2262857054 hasOpenAccess W2262857054 @default.
• W2262857054 hasPrimaryLocation W22628570541 @default.
• W2262857054 hasRelatedWork W2084898420 @default.
• W2262857054 hasRelatedWork W2478385952 @default.
• W2262857054 hasRelatedWork W2591863070 @default.
• W2262857054 hasRelatedWork W2596040508 @default.
• W2262857054 hasRelatedWork W2789722324 @default.
• W2262857054 hasRelatedWork W3049746671 @default.
• W2262857054 hasRelatedWork W3191658268 @default.
• W2262857054 hasRelatedWork W4294693701 @default.
• W2262857054 hasRelatedWork W4309717475 @default.
• W2262857054 hasRelatedWork W2118673085 @default.
• W2262857054 hasVolume "27" @default.
• W2262857054 isParatext "false" @default.

• next